Get the Stockscreener App
79.57
3.21%
-2.64
Inhibrx Biosciences Inc stock is traded at $79.57, with a volume of 179.89K.
It is down -3.21% in the last 24 hours and up +8.52% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$82.21
Open:
$82.14
24h Volume:
179.89K
Relative Volume:
0.51
Market Cap:
$1.16B
Revenue:
$1.80M
Net Income/Loss:
$1.76B
P/E Ratio:
0.6705
EPS:
118.674
Net Cash Flow:
$-149.23M
1W Performance:
-11.07%
1M Performance:
+8.52%
6M Performance:
+455.27%
1Y Performance:
+439.46%
1-Day Range:
$79.20
$83.69
1-Week Range:
$79.00
$94.47
52-Week Range:
$10.80
$94.47
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
79.57 | 1.20B | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Mark Asset Management LP Buys Shares of 17,000 Inhibrx Biosciences, Inc. $INBX - MarketBeat
Franklin Resources Inc. Makes New $316,000 Investment in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences advances sarcoma research with ozekibart trial results - Traders Union
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 5%Here's What Happened - MarketBeat
Inhibrx Biosciences, Inc. $INBX Shares Acquired by Kennedy Capital Management LLC - MarketBeat
With Inhibrx Biosciences Stock Surging, Have You Considered The Downside? - Trefis
Inhibrx Biosciences (NASDAQ:INBX) Trading 6.8% HigherWhat's Next? - MarketBeat
Is Inhibrx Biosciences Inc. stock a buy on dipsDollar Strength & Real-Time Market Trend Scan - Newser
Inhibrx Biosciences stock hits all-time high at 87.89 USD By Investing.com - Investing.com Nigeria
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 52-Week HighHere's Why - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 52-Week High – Here’s Why - Defense World
Why Inhibrx Biosciences Inc. stock is favored by top institutions2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - Newser
Inhibrx Biosciences stock hits all-time high at 87.89 USD - Investing.com
Avoiding Lag: Real-Time Signals in (INBX) Movement - news.stocktradersdaily.com
Inhibrx Biosciences boosts MSTS 2025 with platinum sponsorship - Traders Union
Inhibrx Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Earnings Report: How sustainable is Inhibrx Biosciences Inc. stock dividend payoutBond Market & AI Enhanced Trading Alerts - BỘ NỘI VỤ
Inhibrx Biosciences unveils preclinical progress in glioblastoma treatment - Traders Union
Inhibrx Biosciences Reports Promising Q3 2025 Results - MSN
Inhibrx Biosciences (NASDAQ:INBX) Sets New 1-Year HighHere's Why - MarketBeat
Inhibrx Biosciences stock hits all-time high at 87.4 USD By Investing.com - Investing.com Nigeria
Inhibrx Biosciences stock hits all-time high at 87.4 USD - Investing.com
Discipline and Rules-Based Execution in INBX Response - news.stocktradersdaily.com
Inhibrx Biosciences Inc. (INBX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Inhibrx Biosciences Inc. stock deliver shareholder value2025 Key Highlights & Free Real-Time Volume Trigger Notifications - newser.com
Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap - Seeking Alpha
What high frequency data says about Inhibrx Biosciences Inc.2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - newser.com
Inhibrx Biosciences (NASDAQ:INBX) Trading 7.4% HigherHere's What Happened - MarketBeat
How high can Inhibrx Biosciences Inc. stock go2025 Valuation Update & Risk Controlled Stock Pick Alerts - newser.com
Multi factor analysis applied to Inhibrx Biosciences Inc.Weekly Gains Report & Weekly Watchlist for Hot Stocks - newser.com
Inhibrx Biosciences Inc. stock daily chart insights2025 Technical Patterns & Free Community Supported Trade Ideas - newser.com
How to recover losses in Inhibrx Biosciences Inc. stock2025 Market Outlook & Safe Capital Growth Tips - newser.com
Inhibrx Biosciences stock rating maintained at Market Perform by Citizens - Investing.com South Africa
Is Inhibrx Biosciences Inc. stock a buy in volatile marketsWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Will Inhibrx Biosciences Inc. stock pay special dividendsJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Inhibrx Biosciences Inc (INBX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
Why Inhibrx Biosciences Inc. stock appeals to analystsJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
What Wall Street predicts for Inhibrx Biosciences Inc. stock priceQuarterly Trade Summary & Weekly Top Gainers Trade List - newser.com
Press Release: Inhibrx Reports Third Quarter 2025 Financial Results - 富途牛牛
Inhibrx Misses Estimates Even As New Cancer Drug Shows Promise - Finimize
Assessing Inhibrx Biosciences (INBX) Valuation After Positive Phase 2 Ozekibart Trial Results - Sahm
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):